{"id":66761,"date":"2026-05-29T22:17:18","date_gmt":"2026-05-29T14:17:18","guid":{"rendered":"https:\/\/flcube.com\/?p=66761"},"modified":"2026-05-29T22:17:20","modified_gmt":"2026-05-29T14:17:20","slug":"beone-medicines-and-amgens-tarlatamab-receives-nmpa-conditional-approval-for-second-line-es-sclc-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=66761","title":{"rendered":"BeOne Medicines and Amgen&#8217;s Tarlatamab Receives NMPA Conditional Approval for Second-Line ES-SCLC in China"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>BeOne Medicines Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/ONC:NASDAQ\">NASDAQ: ONC<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/6160:HKG\">HKG: 6160<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/688235:SHA\">SHA: 688235<\/a>), formerly BeiGene, announced it has received <strong>conditional approval<\/strong> from China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> for <strong>Imdelltra (tarlatamab)<\/strong>, a <strong>DLL3-targeting bispecific T-cell engager (BiTE) therapy<\/strong> co-developed with <strong>Amgen<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/AMGN:NASDAQ\">NASDAQ: AMGN<\/a>). The approval expands tarlatamab&#8217;s indication to <strong>extensive-stage small cell lung cancer (ES-SCLC)<\/strong> patients who have progressed after <strong>one prior systemic therapy<\/strong>, including platinum-based chemotherapy.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone-amp-indication-evolution\" class=\"wp-block-heading\">Regulatory Milestone &amp; Indication Evolution<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Regulatory Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Conditional marketing authorization<\/td><\/tr><tr><td><strong>New Indication<\/strong><\/td><td>Second-line ES-SCLC (post-one prior systemic therapy)<\/td><\/tr><tr><td><strong>Previous Approval<\/strong><\/td><td>April 2026: Third-line ES-SCLC treatment<\/td><\/tr><tr><td><strong>Therapeutic Class<\/strong><\/td><td>DLL3-targeting bispecific T-cell engager (BiTE)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-pivotal-clinical-evidence-dellphi-304-study\" class=\"wp-block-heading\">Pivotal Clinical Evidence \u2013 DeLLphi-304 Study<\/h2>\n\n\n\n<h3 id=\"h-global-phase-iii-trial-design\" class=\"wp-block-heading\">Global Phase III Trial Design<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Study Name<\/strong><\/td><td>DeLLphi-304 (NCT05740566)<\/td><\/tr><tr><td><strong>Phase<\/strong><\/td><td>Phase III<\/td><\/tr><tr><td><strong>Design<\/strong><\/td><td>Global, multicenter, randomized, open-label<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>509 patients across 30 countries\/regions<\/td><\/tr><tr><td><strong>Eligibility<\/strong><\/td><td>SCLC progression after platinum-based chemotherapy \u00b1 anti-PD-(L)1 therapy<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 id=\"h-key-efficacy-results\" class=\"wp-block-heading\">Key Efficacy Results<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Tarlatamab<\/th><th>Standard-of-Care Chemotherapy<\/th><th>Improvement<\/th><\/tr><\/thead><tbody><tr><td><strong>Median Overall Survival (OS)<\/strong><\/td><td>13.6 months<\/td><td>8.3 months<\/td><td><strong>+5.3 months<\/strong><\/td><\/tr><tr><td><strong>Death Risk Reduction<\/strong><\/td><td>\u2014<\/td><td>\u2014<\/td><td><strong>40% reduction<\/strong> (HR=0.60)<\/td><\/tr><tr><td><strong>Median Progression-Free Survival (PFS)<\/strong><\/td><td>4.2 months<\/td><td>3.2 months<\/td><td><strong>+1.0 month<\/strong><\/td><\/tr><tr><td><strong>Progression\/Death Risk Reduction<\/strong><\/td><td>\u2014<\/td><td>\u2014<\/td><td><strong>28% reduction<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 id=\"h-safety-profile\" class=\"wp-block-heading\">Safety Profile<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Treatment-Emergent Adverse Events (TEAEs):<\/strong> Generally manageable<\/li>\n\n\n\n<li><strong>Permanent Discontinuation Rate:<\/strong> Low rates of TEAEs leading to treatment discontinuation<\/li>\n\n\n\n<li><strong>Consistency:<\/strong> Safety profile aligns with established BiTE class characteristics<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-drug-mechanism-amp-innovation\" class=\"wp-block-heading\">Drug Mechanism &amp; Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target:<\/strong> Delta-like ligand 3 (DLL3) \u2013 highly expressed on SCLC tumor cells<\/li>\n\n\n\n<li><strong>Platform:<\/strong> Bispecific T-cell engager (BiTE) technology<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Simultaneously binds DLL3 on tumor cells and CD3 on T-cells, redirecting T-cell cytotoxicity to tumor cells<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> First DLL3-targeting BiTE approved in China for SCLC<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-context-amp-competitive-landscape\" class=\"wp-block-heading\">Market Context &amp; Competitive Landscape<\/h2>\n\n\n\n<h3 id=\"h-small-cell-lung-cancer-therapeutic-environment\" class=\"wp-block-heading\">Small Cell Lung Cancer Therapeutic Environment<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Patient Population:<\/strong> Approximately 150,000-200,000 new SCLC cases annually in China<\/li>\n\n\n\n<li><strong>Treatment Challenges:<\/strong> Limited effective options beyond first-line platinum-based chemotherapy<\/li>\n\n\n\n<li><strong>Survival Outcomes:<\/strong> Historically poor prognosis with median OS &lt;10 months in second-line setting<\/li>\n\n\n\n<li><strong>Unmet Need:<\/strong> Significant demand for effective, targeted second-line therapies<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-competitive-sclc-therapies-in-china\" class=\"wp-block-heading\">Competitive SCLC Therapies in China<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Product<\/th><th>Company<\/th><th>Mechanism<\/th><th>Line of Therapy<\/th><th>China Status<\/th><\/tr><\/thead><tbody><tr><td><strong>Tarlatamab (Imdelltra)<\/strong><\/td><td>BeOne\/Amgen<\/td><td>DLL3 BiTE<\/td><td><strong>Second-line<\/strong><\/td><td><strong>NMPA conditional approval<\/strong><\/td><\/tr><tr><td><strong>Immunotherapy Agents<\/strong><\/td><td>Various<\/td><td>PD-(L)1 inhibitors<\/td><td>First-line combination<\/td><td>Approved<\/td><\/tr><tr><td><strong>Topotecan<\/strong><\/td><td>Multiple<\/td><td>Chemotherapy<\/td><td>Second-line standard<\/td><td>Generic available<\/td><\/tr><tr><td><strong>Lurbinectedin<\/strong><\/td><td>Jazz\/PharmaMar<\/td><td>Alkylating agent<\/td><td>Second-line<\/td><td>Not approved in China<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-strategic-partnership-dynamics\" class=\"wp-block-heading\">Strategic Partnership Dynamics<\/h2>\n\n\n\n<h3 id=\"h-beone-medicines-amp-amgen-collaboration\" class=\"wp-block-heading\">BeOne Medicines &amp; Amgen Collaboration<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Development Model:<\/strong> Co-development partnership leveraging BeOne&#8217;s China expertise and Amgen&#8217;s BiTE platform<\/li>\n\n\n\n<li><strong>Commercial Rights:<\/strong> BeOne holds commercial rights in mainland China<\/li>\n\n\n\n<li><strong>Global Strategy:<\/strong> Part of broader international development program<\/li>\n\n\n\n<li><strong>Franchise Expansion:<\/strong> Builds on BeOne&#8217;s established oncology portfolio in China<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-commercial-implications-amp-market-strategy\" class=\"wp-block-heading\">Commercial Implications &amp; Market Strategy<\/h2>\n\n\n\n<h3 id=\"h-for-beone-medicines\" class=\"wp-block-heading\">For BeOne Medicines<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Premium Positioning:<\/strong> First-in-class DLL3 BiTE supports premium pricing<\/li>\n\n\n\n<li><strong>Physician Leverage:<\/strong> Existing relationships with oncology specialists facilitate rapid adoption<\/li>\n\n\n\n<li><strong>Reimbursement Pathway:<\/strong> Strong survival benefit may support favorable NRDL negotiations<\/li>\n\n\n\n<li><strong>Market Leadership:<\/strong> Establishes position in emerging targeted SCLC therapy market<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-china-sclc-market-dynamics\" class=\"wp-block-heading\">China SCLC Market Dynamics<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Diagnostic Infrastructure:<\/strong> Increasing DLL3 testing capabilities in major cancer centers<\/li>\n\n\n\n<li><strong>Healthcare Policy:<\/strong> Government support for innovative oncology therapies addressing unmet needs<\/li>\n\n\n\n<li><strong>Pricing Environment:<\/strong> Value-based pricing justified by 5.3-month OS improvement<\/li>\n\n\n\n<li><strong>Education Needs:<\/strong> Physician training on BiTE administration and toxicity management<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-implementation-timeline-amp-commercial-outlook\" class=\"wp-block-heading\">Implementation Timeline &amp; Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market Launch:<\/strong> Expected Q3 2026<\/li>\n\n\n\n<li><strong>Target Prescribers:<\/strong> Medical oncologists at comprehensive cancer centers<\/li>\n\n\n\n<li><strong>Distribution Strategy:<\/strong> Direct sales force with specialized medical affairs support<\/li>\n\n\n\n<li><strong>Revenue Potential:<\/strong> Estimated \u00a5800 million &#8211; \u00a51.2 billion annual peak sales in Chinese SCLC market<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding market launch, commercial performance, and regulatory compliance for Imdelltra (tarlatamab). Actual results may differ due to risks including market competition, pricing negotiations, healthcare policy changes, and evolving treatment guidelines for small cell lung cancer.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), formerly BeiGene, announced it has received&#8230;<\/p>\n","protected":false},"author":1,"featured_media":66762,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[330,185,2092,847,912,3046,15,848],"class_list":["post-66761","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-amgen","tag-beigene","tag-beone-medicines","tag-hkg-6160","tag-nasdaq-amgn","tag-nasdaq-onc","tag-product-approvals","tag-sha-688235"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>BeOne Medicines and Amgen&#039;s Tarlatamab Receives NMPA Conditional Approval for Second-Line ES-SCLC in China - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), formerly BeiGene, announced it has received conditional approval from China&#039;s National Medical Products Administration (NMPA) for Imdelltra (tarlatamab), a DLL3-targeting bispecific T-cell engager (BiTE) therapy co-developed with Amgen (NASDAQ: AMGN). The approval expands tarlatamab&#039;s indication to extensive-stage small cell lung cancer (ES-SCLC) patients who have progressed after one prior systemic therapy, including platinum-based chemotherapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=66761\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BeOne Medicines and Amgen&#039;s Tarlatamab Receives NMPA Conditional Approval for Second-Line ES-SCLC in China\" \/>\n<meta property=\"og:description\" content=\"BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), formerly BeiGene, announced it has received conditional approval from China&#039;s National Medical Products Administration (NMPA) for Imdelltra (tarlatamab), a DLL3-targeting bispecific T-cell engager (BiTE) therapy co-developed with Amgen (NASDAQ: AMGN). The approval expands tarlatamab&#039;s indication to extensive-stage small cell lung cancer (ES-SCLC) patients who have progressed after one prior systemic therapy, including platinum-based chemotherapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=66761\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-29T14:17:18+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-29T14:17:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2903.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66761#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66761\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"BeOne Medicines and Amgen&#8217;s Tarlatamab Receives NMPA Conditional Approval for Second-Line ES-SCLC in China\",\"datePublished\":\"2026-05-29T14:17:18+00:00\",\"dateModified\":\"2026-05-29T14:17:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66761\"},\"wordCount\":590,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66761#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/2903.webp\",\"keywords\":[\"Amgen\",\"BeiGene\",\"BeOne Medicines\",\"HKG: 6160\",\"NASDAQ: AMGN\",\"NASDAQ: ONC\",\"Product approvals\",\"SHA: 688235\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66761#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66761\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=66761\",\"name\":\"BeOne Medicines and Amgen's Tarlatamab Receives NMPA Conditional Approval for Second-Line ES-SCLC in China - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66761#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66761#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/2903.webp\",\"datePublished\":\"2026-05-29T14:17:18+00:00\",\"dateModified\":\"2026-05-29T14:17:20+00:00\",\"description\":\"BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), formerly BeiGene, announced it has received conditional approval from China's National Medical Products Administration (NMPA) for Imdelltra (tarlatamab), a DLL3-targeting bispecific T-cell engager (BiTE) therapy co-developed with Amgen (NASDAQ: AMGN). The approval expands tarlatamab's indication to extensive-stage small cell lung cancer (ES-SCLC) patients who have progressed after one prior systemic therapy, including platinum-based chemotherapy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66761#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66761\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66761#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/2903.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/2903.webp\",\"width\":1080,\"height\":608,\"caption\":\"BeOne Medicines and Amgen's Tarlatamab Receives NMPA Conditional Approval for Second-Line ES-SCLC in China\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66761#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BeOne Medicines and Amgen&#8217;s Tarlatamab Receives NMPA Conditional Approval for Second-Line ES-SCLC in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"BeOne Medicines and Amgen's Tarlatamab Receives NMPA Conditional Approval for Second-Line ES-SCLC in China - Insight, China&#039;s Pharmaceutical Industry","description":"BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), formerly BeiGene, announced it has received conditional approval from China's National Medical Products Administration (NMPA) for Imdelltra (tarlatamab), a DLL3-targeting bispecific T-cell engager (BiTE) therapy co-developed with Amgen (NASDAQ: AMGN). The approval expands tarlatamab's indication to extensive-stage small cell lung cancer (ES-SCLC) patients who have progressed after one prior systemic therapy, including platinum-based chemotherapy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=66761","og_locale":"en_US","og_type":"article","og_title":"BeOne Medicines and Amgen's Tarlatamab Receives NMPA Conditional Approval for Second-Line ES-SCLC in China","og_description":"BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), formerly BeiGene, announced it has received conditional approval from China's National Medical Products Administration (NMPA) for Imdelltra (tarlatamab), a DLL3-targeting bispecific T-cell engager (BiTE) therapy co-developed with Amgen (NASDAQ: AMGN). The approval expands tarlatamab's indication to extensive-stage small cell lung cancer (ES-SCLC) patients who have progressed after one prior systemic therapy, including platinum-based chemotherapy.","og_url":"https:\/\/flcube.com\/?p=66761","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-29T14:17:18+00:00","article_modified_time":"2026-05-29T14:17:20+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2903.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=66761#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=66761"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"BeOne Medicines and Amgen&#8217;s Tarlatamab Receives NMPA Conditional Approval for Second-Line ES-SCLC in China","datePublished":"2026-05-29T14:17:18+00:00","dateModified":"2026-05-29T14:17:20+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=66761"},"wordCount":590,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=66761#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2903.webp","keywords":["Amgen","BeiGene","BeOne Medicines","HKG: 6160","NASDAQ: AMGN","NASDAQ: ONC","Product approvals","SHA: 688235"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=66761#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=66761","url":"https:\/\/flcube.com\/?p=66761","name":"BeOne Medicines and Amgen's Tarlatamab Receives NMPA Conditional Approval for Second-Line ES-SCLC in China - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=66761#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=66761#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2903.webp","datePublished":"2026-05-29T14:17:18+00:00","dateModified":"2026-05-29T14:17:20+00:00","description":"BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), formerly BeiGene, announced it has received conditional approval from China's National Medical Products Administration (NMPA) for Imdelltra (tarlatamab), a DLL3-targeting bispecific T-cell engager (BiTE) therapy co-developed with Amgen (NASDAQ: AMGN). The approval expands tarlatamab's indication to extensive-stage small cell lung cancer (ES-SCLC) patients who have progressed after one prior systemic therapy, including platinum-based chemotherapy.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=66761#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=66761"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=66761#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2903.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2903.webp","width":1080,"height":608,"caption":"BeOne Medicines and Amgen's Tarlatamab Receives NMPA Conditional Approval for Second-Line ES-SCLC in China"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=66761#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"BeOne Medicines and Amgen&#8217;s Tarlatamab Receives NMPA Conditional Approval for Second-Line ES-SCLC in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2903.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66761","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=66761"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66761\/revisions"}],"predecessor-version":[{"id":66763,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66761\/revisions\/66763"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/66762"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=66761"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=66761"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=66761"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}